Cargando…
Current Treatment of Juvenile Myelomonocytic Leukemia
Juvenile myelomonocytic leukemia (JMML) is a rare pediatric leukemia characterized by mutations in five canonical RAS pathway genes. The diagnosis is made by typical clinical and hematological findings associated with a compatible mutation. Although this is sufficient for clinical decision-making in...
Autores principales: | Mayerhofer, Christina, Niemeyer, Charlotte M., Flotho, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305558/ https://www.ncbi.nlm.nih.gov/pubmed/34300250 http://dx.doi.org/10.3390/jcm10143084 |
Ejemplares similares
-
CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia
por: Fluhr, Silvia, et al.
Publicado: (2016) -
Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research
por: Wehbe, Zeinab, et al.
Publicado: (2021) -
P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK
por: Rajak, Jovana, et al.
Publicado: (2023) -
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
por: Hofmans, Mattias, et al.
Publicado: (2021) -
CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out
por: Dal Molin, Anna, et al.
Publicado: (2021)